Targeting NIPBL may offer a novel strategy to disrupt MYCN-driven transcription and promote tumor cell differentiation in MYCN-amplified neuroblastoma, ultimately improving therapeutic outcomes in this aggressive pediatric cancer. The gene discussed is MYCN; the disease is neoplasm.